NIFTY Pharma TRI

From WebNotes, a public knowledge base. Last updated . Reading time ~7 min.

The NIFTY Pharma Total Returns Index (NIFTY Pharma TRI) is the dividend-reinvested variant of the NIFTY Pharma index, maintained by NSE Indices Limited. The index covers the 20 largest and most liquid pharmaceutical and healthcare-related companies listed on the National Stock Exchange of India (NSE). India is the world’s third-largest pharmaceutical producer by volume and the largest supplier of generic medicines globally; the NIFTY Pharma index reflects this industry’s representation in the Indian equity market. The TRI variant is used as the performance benchmark for pharmaceutical and healthcare sector mutual fund schemes and ETFs.

Publisher and base data

  • Publisher: NSE Indices Limited
  • Base date: 1 January 2001
  • Base value: 1,000
  • Constituent count: 20

Constituent selection and composition

The 20 constituents are drawn from NSE-listed companies in the pharmaceutical and life sciences sectors, including:

  • Bulk drug (API) manufacturers: companies producing active pharmaceutical ingredients.
  • Formulation companies: domestic and export-oriented generic drug manufacturers.
  • Research-based pharmaceutical companies: companies with meaningful R&D investment.
  • Contract research and manufacturing organisations (CRAMOs): increasingly prominent as India’s pharma outsourcing role grows.
  • Hospitals and diagnostics: some healthcare companies beyond pure pharma are included in broader healthcare indices; the NIFTY Pharma index focuses primarily on pharmaceutical companies.

Selection criteria are the same as the broader NIFTY family: free-float market capitalisation rank within the pharmaceutical sector, liquidity screening, and minimum listing history. The index is reconstituted semi-annually. The top five constituents (typically Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Cipla, Divi’s Laboratories, and Aurobindo Pharma or Lupin) account for approximately 60-70% of the index weight.

Methodology

Free-float market capitalisation weighting is used. The TRI layer applies dividend reinvestment on ex-dividend dates. Pharmaceutical companies in India have typically paid modest dividends, with aggregate sector yield in the 0.5-1.0% per annum range. The index is reconstituted semi-annually.

India’s pharmaceutical industry context

Understanding the NIFTY Pharma TRI requires appreciation of India’s pharmaceutical sector’s global position:

  • India supplies approximately 20% of global generics exports by volume.
  • The US is the largest export market, accounting for 30-35% of Indian pharmaceutical exports.
  • The sector is subject to regulatory scrutiny from the US FDA, European EMA, and domestic CDSCO.
  • Earnings are materially affected by: US FDA import alerts, pricing pressures in the US generics market, domestic drug pricing policy, and the rupee-dollar exchange rate.

These sector-specific drivers mean the NIFTY Pharma TRI can diverge sharply from broad market indices during FDA action events or global drug pricing policy changes.

Historical returns

PeriodApproximate NIFTY Pharma TRI CAGR
1-year (FY2024-25)12-18%
3-year CAGR (2022-25)16-22%
5-year CAGR (2020-25)18-24%
10-year CAGR (2015-25)10-15%

The index underperformed the broad market significantly during 2015-2020 due to US FDA regulatory actions, pricing pressures in the US generics market, and the expiry of high-value drug exclusivity windows. The sector rebounded from 2020, aided by the Covid-era demand surge, resolution of FDA issues, and renewed focus on R&D.

Mutual fund and ETF usage

The NIFTY Pharma TRI is the benchmark for:

  • Pharma/healthcare sector funds: examples include Mirae Asset Healthcare Fund, DSP Healthcare Fund, Tata India Pharma & HealthCare Fund, UTI Healthcare Fund.
  • NIFTY Pharma ETFs: exchange-traded products tracking the pharmaceutical sector. Examples: Nippon India ETF Nifty Pharma, Mirae Asset Nifty India Healthcare ETF.

SEBI classifies pharma/healthcare funds as sectoral or thematic funds, which are inherently riskier than diversified equity funds due to concentrated sector exposure. Investors must acknowledge higher risk during scheme subscription.

See also

References

  1. NSE Indices Limited. “NIFTY Pharma Index Methodology.” niftyindices.com. Accessed 2026.
  2. NSE Indices Limited. “NIFTY Pharma Fact Sheet.” niftyindices.com. 2025.
  3. SEBI. Circular SEBI/HO/IMD/DF3/CIR/P/2018/04 on TRI benchmarks.
  4. Pharmaceuticals Export Promotion Council of India (Pharmexcil). “Annual export data.” pharmexcil.com. 2025.

Reviewed and published by

WebNotes Editorial Team

The WebNotes Editorial Team covers Indian capital markets, payments infrastructure and retail investor procedures. Every article is fact-checked against primary sources, principally SEBI circulars and master directions, NPCI specifications and the official support documentation published by the intermediary in question. Drafts go through a second-pair-of-eyes review and a separate compliance read before publication, and revisions are tracked against the SEBI and NPCI rule changes referenced in the methodology section.

Last reviewed
Conflicts of interest
WebNotes is independent. No relationship with any broker, registrar or bank named in this article.